This proposal seeks support to study kappa opioid receptors at the molecular, cellular, anatomical and pharmacological level. These receptors are part of the complex system of endogenous opioids which modulates numerous functions including pain regulation, and drug abuse. The kappa receptors are highly unusual since they mediate pain relief without producing drug dependence. Their activation is responsible for a vast array of effects, ranging from basic physiological functions (such as water balance), to more complex brain functions such as changes in affect or perception. While the existence of these receptors has been shown on the basis of pharmacological data, their molecular structure had not been elucidated. We have recently cloned a member of this kappa family from a rat brain library, based on homology to the newly cloned delta opioid receptor. We have shown that this clone has a seven transmembrane structure typical of the G-protein coupled receptors, and that it binds with high affinity a number of classical kappa ligands and to the products of the prodynorphin precursor. Based on its profile, we have classified it as kappa 1 and shown that its activation by agonists leads to a decrease in forskolin-stimulated cyclic AMP levels. We have demonstrated that this clone has a pattern of tissue expression in the brain characteristic of the kappa 1 site. We have also obtained two related clones from guinea pig, which we tentatively classify as kappa. The proposed project is aimed at completing the task of cloning and characterizing members of the kappa receptor family. Kappa receptor multiplicity is well established, although the exact number of sites is not clear, and the differences across species are very striking. Consequently, a major aim of this proposal is to determine the extent of kappa receptor heterogeneity both within and across species. A related purpose is to fully characterize these receptors in terms of their pharmacological profile, their interactions with endogenous ligands, and their coupling to various signal transduction pathways. Of particular interest is the structure-function determinants of these receptors, both in terms of binding selectivity and coupling mechanisms. This will be studied with molecular techniques used to generate specific mutants and chimeras. The tissue-specific expression of the cloned kappa receptors will be examined in detail, with particular attention to the interface between these receptors and the endogenous ligands. Finally, the last aim is focused on the modulation of these receptors by long-term exposure to opiate agonists and antagonists, be they kappa or mu ligands. These studies should improve our knowledge of these unique receptors and shed light on a number of key mechanisms in which they are involved including pain control, reward and aversiveness, and drug abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA008920-02
Application #
2121773
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1994-06-01
Project End
1999-04-30
Budget Start
1995-06-01
Budget End
1996-04-30
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Psychiatry
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Neal Jr, Charles R; Weidemann, Gabrielle; Kabbaj, Mohamed et al. (2004) Effect of neonatal dexamethasone exposure on growth and neurological development in the adult rat. Am J Physiol Regul Integr Comp Physiol 287:R375-85
Isgor, Ceylan; Shieh, Kun-Ruey; Akil, Huda et al. (2003) Colocalization of estrogen beta-receptor messenger RNA with orphanin FQ, vasopressin and oxytocin in the rat hypothalamic paraventricular and supraoptic nuclei. Anat Embryol (Berl) 206:461-9
Uslaner, Jason M; Norton, Camille S; Watson, Stanley J et al. (2003) Amphetamine-induced c-fos mRNA expression in the caudate-putamen and subthalamic nucleus: interactions between dose, environment, and neuronal phenotype. J Neurochem 85:105-14
Neal Jr, Charles R; VanderBeek, Brian L; Vazquez, Delia M et al. (2003) Dexamethasone exposure during the neonatal period alters ORL1 mRNA expression in the hypothalamic paraventricular nucleus and hippocampus of the adult rat. Brain Res Dev Brain Res 146:15-24
Devine, D P; Hoversten, M T; Ueda, Y et al. (2003) Nociceptin/orphanin FQ content is decreased in forebrain neurones during acute stress. J Neuroendocrinol 15:69-74
Ostrander, M M; Badiani, A; Day, H E W et al. (2003) Environmental context and drug history modulate amphetamine-induced c-fos mRNA expression in the basal ganglia, central extended amygdala, and associated limbic forebrain. Neuroscience 120:551-71
Neal Jr, Charles R; Owens, Constance E; Taylor, Larry P et al. (2003) Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors. J Chem Neuroanat 25:233-47
Ferguson, Susan M; Norton, Camille S; Watson, Stanley J et al. (2003) Amphetamine-evoked c-fos mRNA expression in the caudate-putamen: the effects of DA and NMDA receptor antagonists vary as a function of neuronal phenotype and environmental context. J Neurochem 86:33-44
Owens, Constance E; Akil, Huda (2002) Determinants of ligand selectivity at the kappa-receptor based on the structure of the orphanin FQ receptor. J Pharmacol Exp Ther 300:992-9
Neal Jr, C R; Akil, H; Watson Jr, S J (2001) Expression of orphanin FQ and the opioid receptor-like (ORL1) receptor in the developing human and rat brain. J Chem Neuroanat 22:219-49

Showing the most recent 10 out of 38 publications